CLINICAL TRIALS PROFILE FOR MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

All Clinical Trials for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004361 ↗	Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects	Completed	Ann & Robert H Lurie Children's Hospital of Chicago		1995-07-01	OBJECTIVES: I. Identify latent hypoparathyroidism in normocalcemic adult survivors with repaired conotruncal cardiac defects, by evaluating parathyroid gland secretory function after induced hypocalcemia. II. Determine the relationship of parathyroid hormone secretion to microdeletions in the same region of chromosome 22q11 as found in patients with DiGeorge anomaly.
NCT00004361 ↗	Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects	Completed	National Center for Research Resources (NCRR)		1995-07-01	OBJECTIVES: I. Identify latent hypoparathyroidism in normocalcemic adult survivors with repaired conotruncal cardiac defects, by evaluating parathyroid gland secretory function after induced hypocalcemia. II. Determine the relationship of parathyroid hormone secretion to microdeletions in the same region of chromosome 22q11 as found in patients with DiGeorge anomaly.
NCT00354692 ↗	Effect of Two Iron Preparations on Protein in the Urine	Completed	Watson Pharmaceuticals	Phase 4	2006-06-01	This pilot study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein
NCT00370968 ↗	Zinc-ORS in Severe and Complicated Acute Diarrhea	Completed	All India Institute of Medical Sciences, New Delhi	Phase 2/Phase 3	2003-09-01	Three-hundred-and-fifty-two males aged 1-36 months with acute non-dysenteric diarrhoea and no systemic illness will be enrolled in this clinical trial. Eligible children will be stratified by their age (1up to 5 months, 6-35 months). Within the two age strata the patients will be randomized to receive zinc-ORS (fortified with 40 mg elemental zinc as zinc gluconate per litre) or standard WHO ORS. The major outcome measures will be stool output and duration of diarrhea. The safety of administering zinc will be determined by examining the effect of zinc ingestion on vomiting, sodium and potassium homeostasis, plasma zinc and copper, and iron stores and concentration of serum transferrin receptor.
NCT00370968 ↗	Zinc-ORS in Severe and Complicated Acute Diarrhea	Completed	Centre For International Health	Phase 2/Phase 3	2003-09-01	Three-hundred-and-fifty-two males aged 1-36 months with acute non-dysenteric diarrhoea and no systemic illness will be enrolled in this clinical trial. Eligible children will be stratified by their age (1up to 5 months, 6-35 months). Within the two age strata the patients will be randomized to receive zinc-ORS (fortified with 40 mg elemental zinc as zinc gluconate per litre) or standard WHO ORS. The major outcome measures will be stool output and duration of diarrhea. The safety of administering zinc will be determined by examining the effect of zinc ingestion on vomiting, sodium and potassium homeostasis, plasma zinc and copper, and iron stores and concentration of serum transferrin receptor.

Clinical Trial Conditions for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

Condition Name

Condition Name for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Intervention	Trials
Anemia	3
Kidney Failure, Chronic	2
Anemia, Iron-Deficiency	2
Lymphoproliferative Disorder	1

Condition MeSH

Condition MeSH for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Intervention	Trials
Anemia, Iron-Deficiency	3
Renal Insufficiency	3
Kidney Failure, Chronic	2
Osteoarthritis	2

Clinical Trial Locations for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

Trials by Country

Trials by Country for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Location	Trials
United States	20
Israel	3
Turkey (Trkiye)	2
Mexico	2
Turkey	1

Trials by US State

Trials by US State for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Location	Trials
Arizona	3
Texas	2
Louisiana	2
California	2
Pennsylvania	2

Clinical Trial Progress for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

Clinical Trial Phase

Clinical Trial Phase for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	2
Phase 4	6

Clinical Trial Status

Clinical Trial Status for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Clinical Trial Phase	Trials
Completed	16
Recruiting	4
Unknown status	4

Clinical Trial Sponsors for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

Sponsor Name

Sponsor Name for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Sponsor	Trials
Watson Pharmaceuticals	2
Rambam Health Care Campus	2
Sharpe-Strumia Research Foundation	1

Sponsor Type

Sponsor Type for MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
Sponsor	Trials
Other	40
NIH	4
Industry	4

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE Market Analysis and Financial Projection

Last updated: April 27, 2026

Magnesium chloride + potassium chloride + sodium acetate + sodium chloride + sodium gluconate: Clinical, Market, and Projection View

This drug set is best treated as a set of electrolyte solutions (oral and injectable) rather than a single proprietary “drug.” The clinical use pattern, regulatory posture, and market structure differ by formulation (route, concentration, container, and intended indication) and by whether the product is branded or generic. Across the set, the demand engine is stable: hospitalization, surgery, trauma, chronic comorbidity management, dialysis-adjacent care, and peri-procedural fluid/electrolyte correction.

What clinical trial signals exist for these electrolytes?

For magnesium chloride, potassium chloride, sodium acetate, sodium chloride, and sodium gluconate, clinical development is typically not driven by new mechanistic efficacy trials in late-stage proprietary development the way specialty drugs are. Instead, the clinical landscape is dominated by:

• Formulation and bioequivalence/bridging studies (especially for oral products)
• Comparative trials for infusion safety/compatibility and electrolyte control endpoints
• Perioperative and ICU-focused studies using standard-of-care electrolyte regimens, often without sponsor-owned intellectual property

Because these agents are longstanding, the most decision-relevant “trial updates” for investors are usually tied to:

• ANDA/505(b)(2) approvals and label updates (new dosing, new container types)
• Safety signals related to infusion rates, osmolarity, and compatibility with IV access lines
• Supply and manufacturing constraints that impact availability more than trial outcomes

Given the absence of formulation-specific trial metadata in the prompt (route, concentration, branded product names, NDC/ANDA links, and geographic scope), a complete and accurate cross-trial update cannot be produced without risking fabrication.

How do these agents show up in product-level indications?

Electrolyte solutions and supplements are commonly labeled for:

• Sodium chloride: fluid replacement and electrolyte replenishment; treatment of hyponatremia/hypernatremia in targeted settings; perioperative and emergency resuscitation workflows (concentration and route dependent)
• Potassium chloride: prevention and treatment of hypokalemia; replacement in patients with reduced intake, increased losses, or shifts into cells (route and infusion protocols dependent)
• Magnesium chloride: magnesium replacement (oral) and magnesium repletion (injectable forms, where available)
• Sodium acetate: correction of metabolic acidosis through bicarbonate precursor pathways; perioperative acid-base management (labeling depends on specific solution)
• Sodium gluconate: magnesium and/or metal chelation contexts and electrolyte replenishment; oral magnesium replacement in some formulations; route-specific indications vary

Commercially, each ingredient’s “clinical role” is less about new endpoints and more about integration into hospital protocols: order sets, infusion pumps, and standardized electrolyte monitoring cadence.

---

Market Structure and Competitive Set

How is the market divided for these electrolyte agents?

Electrolyte solutions split into three practical commercial segments:

1. Hospital sterile IV solutions

   • Sodium chloride (0.9% and other strengths), potassium chloride infusions, magnesium-containing IV products, sodium acetate solutions
   • Purchase cycles driven by group purchasing organizations (GPOs), IDNs, and emergency inventory planning

2. Oral electrolyte supplementation

   • Potassium, magnesium (often as salts), and sodium salt regimens
   • Demand influenced by chronic conditions and adherence plus payer coverage

3. Dialysis-adjacent and specialty compounding ecosystems

   • Some electrolyte management occurs via standardized dialysis prescriptions or hospital pharmacy compounding, which shifts measured “product” volumes away from plain ingredient-based counts

What drives unit demand and pricing?

The ingredient list points to a market with these recurring demand drivers:

• Hospital procedure volume: surgery, ED admissions, trauma center utilization
• ICU acuity: sepsis, shock, ventilator care, parenteral nutrition complications
• Renal care mix: dialysis patient throughput and associated electrolyte management
• Seasonality: dehydration-driven admissions increase sodium and fluid replacement needs
• Generic competition and tender dynamics: price is structurally compressed in many geographies

Pricing is typically dominated by:

• Generic penetration
• Packaging format (bag vs vial; concentration; size)
• Regulatory classification (505(b)(2) vs ANDA pathways)
• Supply chain continuity (sterile manufacturing yield and raw material availability)

---

Projection: 3- to 5-Year Outlook

What is the likely growth profile?

Across electrolytes, baseline growth usually tracks with:

• Hospital utilization growth (population and admission trends)
• Ongoing conversion to standardized formularies (increasing adherence to protocolized electrolyte replacement)
• Minimal new trial-driven label expansions (because these are established agents)

In practical terms, the segment’s growth is expected to be:

• Steady to modest in mature markets
• More sensitive to policy and supply than to clinical differentiation
• Concentrated in procurement wins among IDNs and GPOs

What changes the projection outcome materially?

Three factors can move the numbers:

• New sterile manufacturing capacity entering the market (or closures tightening supply)
• Regulatory actions and product recalls that force short-term usage shifts to specific SKUs
• Payer and formulary updates that change which salt forms are preferred (e.g., magnesium salt choice by absorption profile or tolerability)

---

Actionable Business View (What to Do With This Ingredient Set)

Where do commercialization efforts tend to concentrate?

Without proprietary new-moA claims, differentiation usually comes from:

• Formulation stability and compatibility in IV admixture settings (e.g., mixing compatibility with common infusion lines)
• Container and dosing convenience (ready-to-use bags vs smaller vials, reduced handling steps)
• Tolerability and adherence for oral forms
• Hospital-specific protocol alignment (order set fit and nursing workflow)

Which decision levers matter most for R&D?

For these electrolytes, “R&D ROI” typically hinges on:

• Bioequivalence and bridging strategy rather than new efficacy trials
• Safety and infusion workflow studies that de-risk adverse event profiles related to infusion rates and ionic strength
• Manufacturing scale and sterility assurance for sterile products, because supply continuity often drives revenue more than clinical nuance

---

Key Takeaways

• These are electrolyte solutions/salts, not a single drug with a unified clinical development track.
• Clinical trial activity is generally formulation and protocol-oriented rather than new late-stage efficacy platforms.
• Market demand is driven by hospital utilization and ICU acuity, with pricing shaped by generic competition and procurement.
• Near-term revenue growth is expected to be steady and procurement-led, not trial-led, unless supply/regulatory shocks occur.
• Business differentiation typically comes from formulation, container convenience, compatibility, and workflow fit more than from novel clinical endpoints.

---

FAQs

1. Are magnesium chloride, potassium chloride, sodium acetate, sodium chloride, and sodium gluconate considered one drug class commercially?
   Yes in practical procurement and clinical workflow terms (electrolyte replacement). No in IP terms, since product-level formulations and approvals differ.

2. Do late-stage “pivotal” trials exist for these electrolytes?
   Usually not as a dominant pattern. Development more often centers on formulation, equivalence, compatibility, and label-bridging.

3. What is the main purchase channel for IV electrolyte solutions?
   Hospitals through GPO contracts, IDN formularies, and procurement tenders, with pharmacy and nursing workflow requirements shaping selection.

4. Why can sodium and potassium products show different market outcomes despite similar indications?
   Concentration, route, container size, compatibility requirements, and tender-specific contracting drive SKU-level outcomes.

5. What events can rapidly change short-term sales for these agents?
   Sterile manufacturing disruptions, recalls, regulatory actions, and IDN formulary changes tied to procurement and supply stability.

---

Sources

No sources are cited because the prompt does not include product identifiers, geography, time window, or trial/approval references, and producing a numbered citation list without verifiable specifics would risk inaccurate sourcing.